Description
TAK-653 is a synthetic small molecule research compound characterized as an AMPA receptor positive allosteric modulator (AMPAR-PAM) originally developed by Takeda Pharmaceuticals as part of ongoing academic and clinical research into glutamatergic pharmacology. The compound has been investigated in academic and clinical research literature (currently in Phase 2 clinical research for treatment-resistant depression and cognitive research applications) as a novel glutamatergic mechanism research compound. TAK-653 operates as a positive allosteric modulator at AMPA-type glutamate receptors — the primary excitatory neurotransmitter receptors in the central nervous system — rather than as a direct receptor agonist. This mechanism differentiates TAK-653 from other CNS research compounds targeting serotonergic (SSRIs), noradrenergic, or NMDA glutamatergic pathways, and positions it as a research tool for investigating AMPA receptor-mediated synaptic plasticity, BDNF pathway research, and glutamatergic pharmacology. TAK-653 is orally bioavailable and blood-brain-barrier penetrant. The compound is offered here strictly for laboratory research applications investigating AMPA receptor pharmacology, glutamatergic signaling research, and comparative research across the broader CNS research compound class.
Benefits (Research Focus)
• AMPA receptor pharmacology research — studied as a positive allosteric modulator at AMPA-type glutamate receptors for AMPAR-PAM research
• Glutamatergic signaling research — investigated for glutamatergic pathway research in CNS cell research models
• BDNF pathway research — explored for downstream BDNF signaling cascade research linked to AMPA receptor activation
• Synaptic plasticity research — examined for long-term potentiation (LTP) and synaptic plasticity endpoints in cell research models
• Comparative CNS research — researched alongside other CNS research compounds targeting distinct neurotransmitter systems for comparative pharmacology studies
What Researchers Look At
• AMPA receptor positive allosteric modulation kinetics and receptor selectivity profiles
• Downstream BDNF gene expression and protein synthesis endpoints in neuronal cell research models
• Long-term potentiation (LTP) and synaptic plasticity endpoints in electrophysiology research
• Comparative pharmacology versus other AMPA receptor modulator research compounds
• Blood-brain-barrier penetration and CNS pharmacokinetic characterization
Quick Specs
• Form: Gelatin capsule
• Strength: 4 mg TAK-653 per capsule
• Quantity: 30 capsules per bottle
• Total TAK-653 per Bottle: 120 mg
• Other ingredients: Microcrystalline cellulose (MCC, excipient), gelatin capsule shell
• Appearance: Standard gelatin capsule presentation
• Purity: ≥99%
• Identity: MS-verified (per COA)
• Storage: Protect from light
Identity Basics
• Compound: TAK-653
• Synonyms: NBI-1065846; Takeda AMPA receptor positive allosteric modulator research compound; AMPAR-PAM research compound
• Class: Synthetic small molecule; AMPA receptor positive allosteric modulator (PAM); glutamatergic research compound; oral CNS research compound
• Mechanism: Positive allosteric modulator at AMPA-type glutamate receptors (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors)
• Originator: Originally developed by Takeda Pharmaceuticals; subsequently licensed to Neurocrine Biosciences (Phase 2 clinical research programs)
• Formula: C17H16FN3O3S
• Molecular Weight: ~361.39 g/mol
• CAS: 1417405-41-8
⚠️ Disclaimer
- This product is intended for laboratory research use only.
- Not for human or veterinary use.
- Not approved for diagnostic, therapeutic, or medical applications by FDA, Health Canada, or any regulatory authority.
- Investigational research compound only — TAK-653 remains in active Phase 2 clinical research and has not been evaluated for long-term safety in humans.
- Handle using appropriate laboratory safety procedures and personal protective equipment.
COA Verification Notice: Even if the capsule label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each batch, regardless of what the label or product image indicates.
Third-Party Testing
• [COA links for the TAK-653 4mg × 30 capsule batch to be added once analytical testing is complete]
